Several large issuers debuted in the US this past week, and four IPOs joined the pipeline. Sports equipment and apparel maker Amer Sports (AS) priced below the range to raise $1.3 billion at a $6.4 billion market cap. The Finland-based...read more
FibroBiologics' Nasdaq reference price has been set at $8 ahead of its direct listing on Wednesday. The company plans to list on the Nasdaq today under the symbol FBLG. The Nasdaq reference price does not reflect an offering price, or the...read more
Updated Monday, 1/29. Five listings are currently scheduled for the week ahead, although other issuers may join the calendar throughout the week. Leading the pack, sports equipment and apparel maker Amer Sports (AS) plans to raise...read more
FibroBiologics, a Phase 1 biotech developing fibroblast-based therapies for chronic diseases, is expected to begin trading on the Nasdaq on Wednesday, January 31, 2024. ...read more
US IPO Weekly Recap: Amer Sports’ billion-dollar US IPO leads a week of large listings
Several large issuers debuted in the US this past week, and four IPOs joined the pipeline. Sports equipment and apparel maker Amer Sports (AS) priced below the range to raise $1.3 billion at a $6.4 billion market cap. The Finland-based...read more
FibroBiologics' Nasdaq reference price is set at $8 ahead of Wednesday direct listing
FibroBiologics' Nasdaq reference price has been set at $8 ahead of its direct listing on Wednesday. The company plans to list on the Nasdaq today under the symbol FBLG. The Nasdaq reference price does not reflect an offering price, or the...read more
US IPO Week Ahead: Amer Sports tees up its $1.7 billion US IPO
Updated Monday, 1/29. Five listings are currently scheduled for the week ahead, although other issuers may join the calendar throughout the week. Leading the pack, sports equipment and apparel maker Amer Sports (AS) plans to raise...read more
Cell therapy biotech FibroBiologics selects January 31 for Nasdaq direct listing date
FibroBiologics, a Phase 1 biotech developing fibroblast-based therapies for chronic diseases, is expected to begin trading on the Nasdaq on Wednesday, January 31, 2024. ...read more